Praxis Bioresearch LLC, of Menlo Park, Calif., was awarded a $1.5 million fast-track Small Business Innovation Research grant from the National Institutes of Health to support development of PRX-P4-003, an abuse-deterrent dopamine norepinephrine reuptake inhibitor.